COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.
You may also be interested in...
Jonca Bull Brings Clinical Experience To FDA Minority Health Office
Bull returns to the agency after stints at Novartis and Genentech to become director of the Office of Minority Health.
Safety Studies Should Be Required To Retain Celebrex, Bextra Approval – Researcher
Revised approval standards for COX-2 inhibitors still in development should be extended to marketed drugs "as a condition of their retention of approval," Penn researcher FitzGerald tells FDA advisory committee. FitzGerald says Vioxx safety signal is a class effect, calls Pfizer's argument that it is restricted to rofecoxib an "off-target fantasy."
Safety Studies Should Be Required To Retain Celebrex, Bextra Approval – Researcher
Revised approval standards for COX-2 inhibitors still in development should be extended to marketed drugs "as a condition of their retention of approval," Penn researcher FitzGerald tells FDA advisory committee. FitzGerald says Vioxx safety signal is a class effect, calls Pfizer's argument that it is restricted to rofecoxib an "off-target fantasy."